Hongxia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongxia Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Shufeng Wang
National Center of Biomedical Analysis Beijing China
2 shared publications- Ting Xiao
State Key Laboratory of Molecular Oncology Department of Etiology and Carcinogenesis National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
2 shared publications Bo Zheng
Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publicationHaiyang Li
State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
1 shared publicationHao Si
Institute of Mass Spectrometry, Zhejiang Engineering Research Center of Advanced Mass Spectrometry and Clinical Application, School of Material Science and Chemical Engineering, Ningbo University, Ningbo, 315211, China; Zhenhai Institute of Mass Spectrometry, Ningbo, 315211, China
1 shared publicationHuiqin Guo
Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76482
Multi‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance
Ovarian cancer is the deadliest gynecological malignancy. The main obstacle in treating high‐grade serous ovarian cancer (HGSOC) is platinum resistance. The mechanistic interface between tumor metabolic reprogramming and platinum resistance remains undefined. We integrated proteomic and metabolomic profiling of 97 primary HGSOC tumors to map the molecular landscape. Unsupervised clustering identified three subtypes. Subtype 3 exhibited a higher platinum resistance rate (64.5%), as well as worse overall ( p = 0.001) and recurrence‐free ( p = 0.0001) survival. At the molecular level, both Subtypes 2 and 3 tumors displayed phenotypes of activated lipid metabolism. However, Subtype 3 tumors were unique, exhibiting potential divergence between lipid metabolism and bioenergetics. The arachidonic acid metabolism pathway was upregulated ( p = 2.0 × 10 −6 ), and the key enzyme cyclooxygenase‐2 (COX‐2) was overexpressed ( p < 0.001). Subtype 3 tumors exhibited an inflammation‐associated state with the highest infiltration of M2‐like macrophages ( p = 0.007). Single‐cell transcriptomics revealed increased expression of PTGS2 (encoding COX‐2, p = 0.001) and CD163 ( p < 2.2 × 10 −16 ) in macrophages from platinum‐resistant HGSOC. Multiplex immunofluorescence confirmed that platinum‐resistant tumors had a higher proportion of COX‐2 + cells in M2‐like macrophages ( p = 0.010). These findings define a high‐risk HGSOC subtype characterized by inflammation‐related lipid metabolism. This suggests targeting the arachidonic acid metabolism pathway as a way to overcome platinum resistance.
- 17 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76482
Open AccessMulti‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance
Ovarian cancer is the deadliest gynecological malignancy. The main obstacle in treating high‐grade serous ovarian cancer (HGSOC) is platinum resistance. The mechanistic interface between tumor metabolic reprogramming and platinum resistance remains undefined. We integrated proteomic and metabolomic profiling of 97 primary HGSOC tumors to map the molecular landscape. Unsupervised clustering identified three subtypes. Subtype 3 exhibited a higher platinum resistance rate (64.5%), as well as worse overall ( p = 0.001) and recurrence‐free ( p = 0.0001) survival. At the molecular level, both Subtypes 2 and 3 tumors displayed phenotypes of activated lipid metabolism. However, Subtype 3 tumors were unique, exhibiting potential divergence between lipid metabolism and bioenergetics. The arachidonic acid metabolism pathway was upregulated ( p = 2.0 × 10 −6 ), and the key enzyme cyclooxygenase‐2 (COX‐2) was overexpressed ( p < 0.001). Subtype 3 tumors exhibited an inflammation‐associated state with the highest infiltration of M2‐like macrophages ( p = 0.007). Single‐cell transcriptomics revealed increased expression of PTGS2 (encoding COX‐2, p = 0.001) and CD163 ( p < 2.2 × 10 −16 ) in macrophages from platinum‐resistant HGSOC. Multiplex immunofluorescence confirmed that platinum‐resistant tumors had a higher proportion of COX‐2 + cells in M2‐like macrophages ( p = 0.010). These findings define a high‐risk HGSOC subtype characterized by inflammation‐related lipid metabolism. This suggests targeting the arachidonic acid metabolism pathway as a way to overcome platinum resistance.
- 3 December 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 239, 115869
Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker
- 3 December 2023
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 239, 115869
Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker